Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal completes Kashiv BioSciences acquisition, issues 28,942,098 shares

Neutral Impact 4 of 5 m&a Written later

Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, paying in part with 28,942,098 newly issued Class A shares. The company also borrowed a $350 million incremental term loan, with proceeds used as part of the purchase consideration, and says the deal adds a long-term biosimilars growth pillar. The filing does not disclose financial results or the total purchase price, so the effect on earnings and the share count is not yet quantified.

Key points

  • Acquisition of Kashiv BioSciences, LLC closed on August 10, 2026, under a Membership Interest Purchase Agreement dated April 21, 2026
  • Amneal issued 28,942,098 shares of Class A Common Stock to the sellers in a private placement exempt from registration
  • $350 million incremental term loan made by Bank of America, N.A. under Amendment No. 4 to the Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as agent
  • Amneal plans to file Kashiv financial statements and pro forma information by amendment, and to register the shares for resale on Form S-3

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:05 PM ET
Accession number0001140361-26-032014

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.